Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
نویسندگان
چکیده
منابع مشابه
Checkpoint blockade immunotherapy for cancer comes of age.
Cancer immunotherapy—Science’s 2013 breakthrough of the year—took off in 2014. Almost weekly, reports described patients on immunotherapies living longer than those taking combinations of chemotherapy and targeted drugs. One immunotherapy has reenergized the field. Ipilimumab (Yervoy), the first checkpoint inhibitor developed, approved in the U.S. in 2011, is the culmination of more than two de...
متن کاملA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
The last several years have witnessed exciting progress in the development of immunotherapy for the treatment of cancer. This has been due in great part to the development of so-called checkpoint blockade. That is, antibodies that block inhibitory receptors such as CTLA-4 and PD-1 and thus unleash antigen-specific immune responses against tumors. It is clear that tumors evade the immune respons...
متن کاملCheckpoint Blockade in Cancer Immunotherapy: Squaring the Circle
Manipulating the complex interaction between the immune system and tumour cells has been the focus of cancer research for many years, but it is only in the past decade that significant progress has been made in the field of cancer immunotherapy resulting in clinically effective treatments. The blockade of coinhibitory immune checkpoints, essential for maintaining lymphocyte homeostasis and self...
متن کاملPotential of cancer-testis antigens as targets for cancer immunotherapy
Cancer-testis antigens are tumour antigens with limited expression in male germ cells in the testis, ovary and trophoblasts. Recently, their expression has been seen in different types of tumours. Due to the existence of the blood-testis barrier, testis is considered an immune-privileged site; and testis-specific genes, if expressed in cancers, can be immunogenic. For this reason, cancertestis ...
متن کاملCancer-testis antigens: potential targets for cancer immunotherapy.
Cancer-testis antigens are tumor antigens that their expression is almost limited to male germ cells in the testis. Some of cancer-testis antigens are also expressed in the ovary and in trophoblasts. Recently their expression has been seen in different types of tumors. Many pathophysiologic studies suggest that a blood-testis barrier exists in the testis. Because spermatogenesis begins at puber...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature
سال: 2014
ISSN: 0028-0836,1476-4687
DOI: 10.1038/nature13988